Financial Contrast: Shionogi & Co., Ltd. (SGIOY) versus Its Competitors

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) is one of 400 publicly-traded companies in the “Private households” industry, but how does it contrast to its competitors? We will compare Shionogi & Co., Ltd. to similar businesses based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, valuation, risk and dividends.

Profitability

This table compares Shionogi & Co., Ltd. and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd.	43.92%	18.01%	15.54%
Shionogi & Co., Ltd. Competitors	-16.59%	6.63%	1.96%

Volatility and Risk

Shionogi & Co., Ltd. has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd.’s competitors have a beta of 2.27, meaning that their average share price is 127% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Shionogi & Co., Ltd. shares are owned by institutional investors. Comparatively, 13.4% of shares of all “Private households” companies are owned by institutional investors. 4.1% of shares of all “Private households” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Shionogi & Co., Ltd. and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd.	1	0	0	0	1.00
Shionogi & Co., Ltd. Competitors	1454	4269	4303	48	2.29

As a group, “Private households” companies have a potential upside of 1,337.35%. Given Shionogi & Co., Ltd.’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Shionogi & Co., Ltd. has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Shionogi & Co., Ltd. and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Shionogi & Co., Ltd.	$2.99 billion	$1.02 billion	8.60
Shionogi & Co., Ltd. Competitors	$12.66 billion	$1.31 billion	14.86

Shionogi & Co., Ltd.’s competitors have higher revenue and earnings than Shionogi & Co., Ltd.. Shionogi & Co., Ltd. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Dividends

Shionogi & Co., Ltd. pays an annual dividend of $0.19 per share and has a dividend yield of 1.7%. Shionogi & Co., Ltd. pays out 15.0% of its earnings in the form of a dividend. As a group, “Private households” companies pay a dividend yield of 1.4% and pay out 34.8% of their earnings in the form of a dividend. Shionogi & Co., Ltd. is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.

Summary

Shionogi & Co., Ltd. competitors beat Shionogi & Co., Ltd. on 10 of the 15 factors compared.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.